Telix Pharmaceuticals

The Business

Telix is a radiopharmaceutical company built around two FDA-approved PSMA-PET prostate cancer imaging agents, Illuccix and Gozellix, which together drive roughly 81% of group revenue. The company also owns more than 30 U.S. radiopharmacies through its RLS subsidiary, giving it direct control over manufacturing and distribution of isotopes that decay within hours and that competitors typically source from third parties. Beyond diagnostics, Telix is developing a therapeutic pipeline, most notably ProstACT, an antibody-based prostate cancer treatment partnered 50/50 with Regeneron, alongside earlier-stage kidney imaging and oncology programs.

Recent Performance

The shares have re-rated sharply over the past year as the diagnostic business scaled and pipeline optimism built, with revenue growing 56% in FY25 on top of 55% growth in FY24, an unusually strong two-year run. That momentum has carried into FY26, with revenue tracking toward company guidance of $950-970 million for the full year. Two regulatory setbacks, Complete Response Letters for both Zircaix and Pixclara within twelve months, have tempered enthusiasm without derailing the broader re-rating.

Outlook

Revenue growth is set to decelerate over the next two to three years as the PSMA-PET market matures and the current period of exceptional growth normalises toward a more sustainable pace. The more important shift is margin. Group EBITDA margin is expected to improve materially over that period as radiopharmacy losses narrow toward breakeven and research spending eases off its current elevated share of revenue. Net profit is expected to turn positive within the next two years and then scale further as the commercial business matures and pipeline-related spending moderates.

Key Risks

A failed ProstACT Phase 3 trial, the base-rate outcome for antibody therapies at this stage roughly 70% of the time, would represent the single largest setback to the thesis, given how much of the pipeline value depends on its success. A third Complete Response Letter, following two in the past twelve months, would raise legitimate questions about Telix's regulatory execution more broadly and further dent sentiment ahead of any resolution. Generic competition in PSMA imaging is also emerging as a structural risk: a generic application for gallium-68 PSMA-11 has already been filed, and approval within two to three years could compress Precision Medicine gross margins by 300-500 basis points.

What to Watch

The thesis-defining event is the Pixclara FDA decision on September 11, 2026, the first real test of whether pipeline expectations embedded in the current price are realistic or overly optimistic. Zircaix's resubmission over the following 12-18 months and early signs from ProstACT enrolment through 2027 will further shape the picture.

• Sept 11, 2026 Pixclara FDA decision — approval or a third CRL will re-rate sentiment on the entire pipeline.
• Mid-2027 to 2028-29 ProstACT enrolment and interim data — the central swing factor in the pipeline outlook.

Company Description

Telix Pharmaceuticals operates across two main lines: Precision Medicine (Px), its diagnostic imaging franchise, and Telix Manufacturing Solutions (TMS), its radiopharmacy and isotope supply network. Px centres on Illuccix and Gozellix, both gallium-68 PSMA-PET imaging agents used to detect and stage prostate cancer, together accounting for approximately 81% of group revenue. TMS operates more than 30 owned U.S. radiopharmacies, acquired via RLS, that manufacture and distribute short-half-life isotopes both for Telix's own products and increasingly as a standalone service. A third, smaller but strategically important arm is the therapeutics pipeline: ProstACT for metastatic prostate cancer (partnered with Regeneron), Zircaix for kidney imaging, and earlier programs LUTEON and IPAX BrIGHT, none of which yet generate meaningful revenue.

Where the Growth Is

Precision Medicine remains the growth engine, contributing roughly 81% of group revenue and still expanding, though the pace is slowing as the PSMA-PET market matures. Growth has decelerated from around 27% year-on-year most recently to an expected 15-18% next year, settling toward a longer-run 11-12% compound rate as penetration of the addressable scan population climbs from an estimated 25% today. This volume growth, combined with radiopharmacy losses narrowing toward breakeven, is the primary driver behind the expected step-up in group profitability over the next few years.

Competitive Position

Telix holds the number two position in U.S. PSMA-PET imaging, and its advantage is structural rather than purely product-based. Owning more than 30 radiopharmacies gives it direct control over manufacturing and same-day distribution of isotopes with half-lives measured in hours, a logistics requirement that is expensive and slow for competitors to replicate, worth an estimated 300 basis points of gross margin advantage. Telix is also the only company with two FDA-approved PSMA agents, capturing both major gallium-68 workflow preferences among nuclear medicine practices. That advantage is narrowing rather than widening: a generic application for gallium-68 PSMA-11 has already been filed, and approval within two to three years would compress margins as pricing power erodes. The moat holds for three to five years on the diagnostic business alone, extending toward seven to ten years only if the therapeutic pipeline succeeds and creates a genuine combined diagnostic-and-therapy platform.

Management & Capital Discipline

Founder-CEO Christian Behrenbruch has taken Telix from pre-revenue to an estimated $960 million run-rate in under a decade, and revenue guidance has been met or exceeded in every year we can verify. Capital has gone predominantly toward the RLS radiopharmacy acquisition, a well-timed convertible bond refinancing, and an aggressive research program running three pivotal trials simultaneously at 26% of revenue, a level benchmarked against peers such as Lantheus and Novartis. The honest observation is that two FDA Complete Response Letters in twelve months, for Zircaix and Pixclara, point to genuine regulatory execution gaps rather than bad luck. Management disclosed both issues promptly, supporting credibility on transparency, but that does not offset the underlying execution risk heading into the Pixclara decision.

Financial Position

Telix held approximately $252 million in cash at the last half-year mark against total debt near $516 million, dominated by a $600 million face-value convertible bond due 2031 carrying no financial covenants. Net debt sits around 2.5 times trailing EBITDA, manageable given the low coupon and long maturity, though the convertible represents a 15-25% dilution overhang if converted. Free cash flow is only marginally positive over the next two years as the business keeps investing in the pipeline and radiopharmacy network. The balance sheet can comfortably weather near-term volatility, but has limited room to absorb a large one-off cost, such as an SEC settlement, without raising equity.